Fig. 1

BCL9 suppression promotes CD8⁺ T cells infiltration. a CT26 cells transduced with non-targeting (NT)-shRNA or Bcl9-shRNA were inoculated in BALB/c mice (n = 5 per cohort). b MC38 cells transduced with non-targeting (NT)-shRNA or Bcl9-shRNA were inoculated in C57BL/6 mice (n = 6 per cohort). c Image of tumor tissue from (c). d Tumor growth in Bcl9^+/+ (wild-type) and Bcl9^–/– (Bcl9 knockout) mice injected subcutaneously (s.c.) with MC38 cells. e qRT-PCR measurement of Cd44 and Axin2 expression in CT26 tumor tissue treated with hsBCL9_CT-24 (i.p., 25 mg/kg) or vehicle. f Percentage of GZMB⁺ cells among CD45⁺CD8⁺ T cells in tumors from (a) was analyzed. g Percentage of IFN-γ⁺ cells among CD45⁺CD8⁺ T cells in tumors from (a) was analyzed. h Percentage of GZMB⁺ cells among CD45⁺CD8⁺ T cells in tumors from (b) was analyzed. i Percentage of IFN-γ⁺ cells among CD45⁺CD8⁺ T cells in tumors from (b) was analyzed. j Percentage of GZMB⁺ cells among CD45⁺CD8⁺ T cells in tumors from (c) was analyzed. k Percentage of IFN-γ⁺ cells among CD45⁺CD8⁺ T cells in tumors from (c) was analyzed. Results were denoted as means ± SEM for experiments performed in triplicate. Each experiment was repeated three times, and the statistical significance of differences between groups was determined by Two-way ANOVA or non-parametric test (One-tailed or Two-tailed). P < 0.05 means statistically significant.